NDAORALTABLET
Approved
Oct 2002
Lifecycle
Post-LOE
Competitive Pressure
35/100
Clinical Trials
20
Data completeness
6/8 — Strong
ZETIA (ezetimibe) by Merck & Co. is intestine. Approved for hypercholesterolemia, dyslipidemia, coronary artery disease and 2 more indications. First approved in 2002.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZETIA (ezetimibe) is a small-molecule dietary cholesterol absorption inhibitor that works by blocking the NPC1L1 sterol transporter at the intestinal brush border, reducing cholesterol uptake and increasing hepatic LDL receptors. It is indicated as monotherapy or in combination with statins for hypercholesterolemia management. The drug reduces LDL cholesterol by decreasing intestinal cholesterol delivery to the liver.
$7MPart D
LOE ApproachingDeclining
Post-LOEProduct is in terminal LOE phase with minimal Part D spending; commercial teams are likely transitioning to generic support or deprioritized as market exclusivity ends.
Mechanism of Action
intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of…
Pharmacologic Class:
Dietary Cholesterol Absorption Inhibitor
Indications (5)
Worked on ZETIA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.